Clinical Trial

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Study acronym: Preselect-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-07.
Trial Details
NCT Number NCT07023484
Lead Sponsor The University of Hong Kong
Collaborators: Queen Mary Hospital, Hong Kong, United Christian Hospital, Pamela Youde Nethersole Eastern Hospital, The University of Hong Kong-Shenzhen Hospital, Sun Yat-Sen University Cancer Center
Conditions Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Enrollment 126 participants
Start Date 2025-05-22
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-02